Anti-inflammatory and immune stimulating effects of trekrezan in treatment of of inflammatory and degenerative damages of the smooth parodont tissue

Shabanov, Petr Dmitriyevich; Дмитриевич, Шабанов Петр; Mokrenko, E.V.; Владимирович, Мокренко Евгений

doi:10.17816/rcf13234-42

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(7)(8)(9)(10)(11) Krezacin (hydroxyethylammonium methylphenoxyacetate) and Metaprot (ethylthiobenzimidazole hydrobromide monohydrate) were created in Russia in the middle of the last century and proved to have antihypoxic, energy-stabilizing (ergotropic) and immunomodulating properties. (12)(13)(14)(15)(16) However, studies of these medicines regarding bronchopulmonary diseases have not been carried out.…”

Section: Introductionmentioning

confidence: 99%

Cytokine Profile and Its Correction by Immunomodulators in Experimental Bronchopulmonary Inflammation in Rats

Darenskaya¹,

Mokrenko²,

Shabanov³

et al. 2019

IJBM

View full text Add to dashboard Cite

The aim of this study was to assess the changes in the levels of the blood serum pro-and anti-inflammatory cytokines in rats with experimental bronchopneumonia and after administration of immunomodulators. Materials and Methods: Research was carried out on mature male Wistar rats (n=111), weighing 220-250g. The bronchopulmonary inflammation in the rats was modeled by administration of 0.1 ml of gum turpentine in the rats' trachea under etherization. All rats were divided into four groups: Group 1 included intact animals (n=18); Group 2 included animals having bronchopneumonia (n=19); Group 3 included animals having bronchopneumonia treated with Krezacin (n=15); Group 4 included animals having bronchopneumonia treated with Metaprot (n=16). Right after the operation and for the next 5 days, a solution of one of the test immunomodulators was injected (once a day) abdominally in the experimental animals: 25mg/kg of Krezacin or 25mg/kg of Metaprot. On Day 5 of the experiment, the animals were decapitated under anesthesia and blood samples were collected. The concentration of cytokines in the blood was determined by the flow immunofluorometry method with the device Bio-RadLaboratories (USA). Results: The administration of Krezacin in animals with bronchopneumonia, in comparison with untreated animals, was accompanied by a statistically significant increase in the levels of IL-1β (by 3.43 times), IL-2 (by 1.95 times), INF-γ (by 3.29 times), and MCP-1 (by 2.07 times) and a decrease in the levels of TNFα (by 1.85 times) and IL-6 (by 2.20 times). Administration of Krezacin increased anti-inflammatory cytokines considerably: IL-4 by 5.22 times and IL-10 by 2.41 times. Analysis of results after administration of Metaprot demonstrates an increase in the levels of IL-1β (by 2.57 times), IL-2 (by 2 times), INF-γ (by 3.21 times), and MCP-1 (by 1.98 times) and a decrease in the levels of TNFα (by 2.17 times) and IL-6 (by 2.5 times), compared to data on untreated animals. Anti-inflammatory cytokines also increased greatly: IL-4 by 5.3 times and IL-10 by 3.71 times. Conclusion: The results obtained show that investigated preparations reduce the severity and intensity of bronchopneumonia in rats. Krezacin and Metaprot demonstrate the properties of true immunomodulators, increasing protective properties of cytokines and providing the adaptive response of the body in severe bronchopulmonary pathology.

show abstract

Section: Introductionmentioning

confidence: 99%

Cytokine Profile and Its Correction by Immunomodulators in Experimental Bronchopulmonary Inflammation in Rats

Darenskaya¹,

Mokrenko²,

Shabanov³

et al. 2019

IJBM

View full text Add to dashboard Cite

show abstract

Hydroxyethylammonium methylphenoxyacetate, immunomodulator and adaptogen: clinical use review

Rybachkova

2022

Медицинская Этика

View full text Add to dashboard Cite

Oxyethylammonium methylphenoxyacetate is an adaptogenic immunomodulator with a complex mechanism of action. It can be successfully used for treatment, prevention and restoration in case of flu and cold, and to improve working capacity in asthenia, including conditions developed following COVID‑19. Clinical investigation of the effect produced by oxyethylammonium methylphenoxyacetate demonstrates its effectiveness under extreme climate and geographic conditions, during physical and mental overload, exercise, viral infections, severe infectious pathology, and all diseases associated with a weakened immune system. Based on conducted clinical trials of oxyethylammonium methylphenoxyacetate, no adverse effects were found and good tolerability was observed. Due to good compatibility of oxyethylammonium methylphenoxyacetate with other agents, it can be included into complex rehabilitation programs as an independent or/and complementary agent. This increases effectiveness of the conducted treatment and improves the diagnosis.

show abstract

Anti-inflammatory and immune stimulating effects of trekrezan in treatment of of inflammatory and degenerative damages of the smooth parodont tissue

Cited by 2 publications

References 0 publications

Cytokine Profile and Its Correction by Immunomodulators in Experimental Bronchopulmonary Inflammation in Rats

Cytokine Profile and Its Correction by Immunomodulators in Experimental Bronchopulmonary Inflammation in Rats

Hydroxyethylammonium methylphenoxyacetate, immunomodulator and adaptogen: clinical use review

Contact Info

Product

Resources

About